Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Drug-related morbidity and mortality. A cost-of-illness model.

Johnson JA, Bootman JL.

Arch Intern Med. 1995 Oct 9;155(18):1949-56.

PMID:
7575048
2.

The health care cost of drug-related morbidity and mortality in nursing facilities.

Bootman JL, Harrison DL, Cox E.

Arch Intern Med. 1997 Oct 13;157(18):2089-96.

PMID:
9382665
3.

Drug-related morbidity and mortality: updating the cost-of-illness model.

Ernst FR, Grizzle AJ.

J Am Pharm Assoc (Wash). 2001 Mar-Apr;41(2):192-9.

PMID:
11297331
4.

New technologies and potential cost savings related to morbidity and mortality reduction in Class III/IV heart failure patients in Canada.

Bentkover JD, Stewart EJ, Ignaszewski A, Lepage S, Liu P, Cooper J.

Int J Cardiol. 2003 Mar;88(1):33-41.

PMID:
12659982
5.

The economic burden of depression in 1990.

Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER.

J Clin Psychiatry. 1993 Nov;54(11):405-18.

PMID:
8270583
6.

Acute coronary syndromes in Europe: 1-year costs and outcomes.

Taylor MJ, Scuffham PA, McCollam PL, Newby DE.

Curr Med Res Opin. 2007 Mar;23(3):495-503.

PMID:
17355731
7.

Cost of depression in Europe.

Sobocki P, J├Ânsson B, Angst J, Rehnberg C.

J Ment Health Policy Econ. 2006 Jun;9(2):87-98.

PMID:
17007486
8.

Economic costs of diabetes in the U.S. In 2007.

American Diabetes Association.

Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Review. Erratum in: Diabetes Care. 2008 Jun;31(6):1271.

PMID:
18308683
10.

Can clinical pharmacy services have a positive impact on drug-related problems and health outcomes in community-based older adults?

Hanlon JT, Lindblad CI, Gray SL.

Am J Geriatr Pharmacother. 2004 Mar;2(1):3-13. Review.

PMID:
15555474
11.

Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction.

White AG, Birnbaum HG, Rothman DB, Katz N.

Appl Health Econ Health Policy. 2009;7(1):61-70. doi: 10.2165/00148365-200907010-00006.

PMID:
19558195
12.

Counting the costs of drug-related adverse events.

White TJ, Arakelian A, Rho JP.

Pharmacoeconomics. 1999 May;15(5):445-58. Review.

PMID:
10537962
13.

Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems.

Westerlund T, Marklund B.

J Clin Pharm Ther. 2009 Jun;34(3):319-27. doi: 10.1111/j.1365-2710.2008.01017.x.

PMID:
19646078
14.

The costs associated with adverse drug events among older adults in the ambulatory setting.

Field TS, Gilman BH, Subramanian S, Fuller JC, Bates DW, Gurwitz JH.

Med Care. 2005 Dec;43(12):1171-6.

PMID:
16299427
16.

The economic burden of skin disease in the United States.

Dehkharghani S, Bible J, Chen JG, Feldman SR, Fleischer AB Jr.

J Am Acad Dermatol. 2003 Apr;48(4):592-9.

PMID:
12664024
17.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
18.

Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients.

Delong LK, Culler SD, Saini SS, Beck LA, Chen SC.

Arch Dermatol. 2008 Jan;144(1):35-9. doi: 10.1001/archdermatol.2007.5.

PMID:
18209166
19.

Economic costs of diabetes in the US in 2002.

Hogan P, Dall T, Nikolov P; American Diabetes Association.

Diabetes Care. 2003 Mar;26(3):917-32.

PMID:
12610059
20.

The economic burden of schizophrenia in the United States in 2002.

Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J.

J Clin Psychiatry. 2005 Sep;66(9):1122-9.

PMID:
16187769

Supplemental Content

Support Center